Bradley Mark Christopher sold $68K of ALMS

Bradley Mark Christopher (Chief Development Officer) sold 2,572 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Bradley Mark Christopher
Published Aug 5, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the named officer, including price, shares, and post-transaction holdings.

02

Market read

Traders may note insider selling, but the filing alone is usually not a standalone catalyst for repricing.

03

What to watch

The article does not provide context for the sale (taxes, scheduled liquidity needs, or prior grants), so interpreting it as a strong signal is risky.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05 after-hours; transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS disclosed an insider open-market sale by its Chief Development Officer of 2,572 shares at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades unless accompanied by other company-specific news.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no accompanying guidance, operational update, or enforcement/regulatory action.

Market effects

Minimal, as this is company-specific insider trading with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; the absence of a stated 10b5-1 plan does not automatically imply bearish information.

Key entities

  • ALUMIS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Bradley Mark Christopher

    Chief Development Officer who sold 2,572 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.